Drug
Ion440
Ion440: highest development phase Phase 1/2, developed by Ionis Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Ionis Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| ION440 NCT06430385 | Phase 1/2 | Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome |
Latest
No recent events.
Follow Ion440 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.